Abivax (ABVX) Research & Development (2022 - 2026)

Abivax's Research & Development history runs 5 years deep, the most recent figure standing at -$58.0 million for Q1 2026.

• In Q1 2026, Research & Development fell 40.3% year-over-year to -$58.0 million; the TTM figure through Mar 2026 stood at -$218.3 million (down 35.38% YoY), while the FY2025 annual figure was -$207.0 million, down 32.21% from the prior year.
• Research & Development for Q1 2026 stood at -$58.0 million, down from -$51.7 million in the prior quarter.
• The five-year high for Research & Development was -$49.28 in Q4 2022, with the low at -$64.8 million in Q3 2025.
• The 5-year median for Research & Development is -$41.3 million (2025), against an average of -$38.0 million.
• The sharpest annual moves came in 2024 and 2025: Research & Development plunged 37113036.64% in 2024, then declined 6.46% in 2025.
• Abivax's Research & Development stood at -$49.28 in 2022, then plunged by 125.33% to -$111.04 in 2023, then slumped by 37113036.64% to -$41.2 million in 2024, then retreated by 25.52% to -$51.7 million in 2025, then retreated by 12.13% to -$58.0 million in 2026.
• Business Quant data shows ABVX's Research & Development at -$58.0 million in Q1 2026, -$51.7 million in Q4 2025, and -$64.8 million in Q3 2025.